Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
详细信息 查看全文
- 作者：Tony Moka ; tony@clo.cuhk.edu.hk" class="auth_mail" title="E-mail the corresponding author ; Guia Ladrerab ; Vichien Srimuninnimitc ; Virote Sriuranpongd ; Chong-Jen Yue ; Sumitra Thongprasertf ; Jennifer Sandoval-Tang ; Jin Soo Leeh ; Fatima Fuertei ; David S. Shamesj ; Barbara Klughammerk ; Matt Trumank ; Pablo Perez-Morenok ; Yi-Long Wul ; syylwu@live.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：EGFR ; epidermal growth factor receptor ; TKIs ; tyrosine-kinase inhibitors ; NSCLC ; non-small-cell lung cancer ; PFS ; progression-free survival ; FISH ; fluorescence in-situ hybridization ; IHC ; immunohistochemistry ; ERCC1 ; excision repair cross-complementation group 1 ; ECOG ; Eastern Cooperative Oncology Group ; PS ; performance status ; RECIST ; Response Evaluation Criteria in Solid Tumors ; OS ; overall survival ; NPR ; non-progression rate ; ORR ; objective response rate ; FACT-L ; Functional Assessment of Canc
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：98
- 期：Complete
- 页码：1-8
- 全文大小：1158 K
文摘
- m" id="list_lis0005">
- •
- •
Expression of HER2 and HER3 were not independently predictive of treatment benefit.
- •
ERCC1 status may be predictive of treatment outcomes in